Treatment Patterns at End of Life in Pediatric Inpatients With Cancer
Investigators assessed the patterns in medication utilization among pediatric inpatients with cancer in their last week of life.
All articles by Jonathan Goodman, MPhil
Effects of Daratumumab on Patient-Reported Outcomes, HRQOL in Newly Diagnosed Multiple Myeloma
Investigators reported the results of the phase 3 MAIA trial on HRQOL outcomes in patients with transplant-ineligible, newly diagnosed MM.
Improvements Seen in Allogeneic Stem Cell Transplantation-Related Mortality
Experts assessed mortality rates linked to allogeneic stem cell transplantation in the past 40 years using data from the European Society for Blood and Marrow Transplantation registry.
Subcutaneous Bortezomib Plus Panobinostat May Reduce Toxicity in R/R Multiple Myeloma
For patients with relapsed or refractory multiple myeloma, subcutaneous bortezomib may improve the tolerability of combination panobinostat, bortezomib, and dexamethasone.
Myelodysplastic Syndromes: Gene Expression Signatures May Predict Response to Azacitidine
Among some patients with myelodysplastic syndrome, gene expression signatures appear to be predictive of response and primary resistance to azacitidine.
Adherence to Allogeneic Stem Cell Transplantation to Improve Survival in Myelodysplastic Syndromes
With the exception of alloSCT and iron chelation therapy, many guideline treatments may not improve survival among patients with myelodysplastic syndrome.
Venous Thromboembolism Risk Steadily Increasing in Cancer
The risk for venous thromboembolism is steadily increasing among patients with cancer compared with the general population.
Mantle Cell Lymphoma: Analysis Reveals Real-World Patient Experiences With Ibrutinib
A retrospective analysis highlights the reasons for discontinuation of ibrutinib among patients with mantle cell lymphoma.
Anti-CD19 CAR T-Cell Therapy Effective in Relapsed/Refractory B-Cell Acute Lymphocytic Leukemia
Investigators aimed to determine and compare outcomes in patients with relapsed or refractory ALL who were treated with anti-CD19 CAR T-cell therapy.
Survival Outcomes in Acute Myeloid Leukemia Associated With Measureable Residual Disease Status
Among patients with acute myeloid leukemia, minimal residual disease-negativity may be linked to improved survival rates.
-
Loading...
-
Loading...
Next post in Hematologic Cancers
